Your browser doesn't support javascript.
loading
Low Pneumococcal Vaccination among Patients with Psoriasis in Germany: Results from Vac-Pso.
Wellmann, Phoebe; Kromer, Christian; Siemer, Ralf; Klein, Selina; Mohr, Johannes; Lippert, Undine; Pinter, Andreas; Wilsmann-Theis, Dagmar; Mössner, Rotraut.
Afiliação
  • Wellmann P; Department of Dermatology, University Medical Center Göttingen, 37075 Göttingen, Germany.
  • Kromer C; Department of Dermatology, University Medical Center Göttingen, 37075 Göttingen, Germany.
  • Siemer R; Faculty of Mathematics and Computer Science, University of Göttingen, 37073 Göttingen, Germany.
  • Klein S; Department of Dermatology and Allergy, University Bonn, 53127 Bonn, Germany.
  • Mohr J; Department of Dermatology, University Medical Center Göttingen, 37075 Göttingen, Germany.
  • Lippert U; Department of Dermatology, University Medical Center Göttingen, 37075 Göttingen, Germany.
  • Pinter A; Department of Dermatology, Venerology and Allergology, University of Frankfurt, 60590 Frankfurt am Main, Germany.
  • Wilsmann-Theis D; Department of Dermatology and Allergy, University Bonn, 53127 Bonn, Germany.
  • Mössner R; Department of Dermatology, University Medical Center Göttingen, 37075 Göttingen, Germany.
Vaccines (Basel) ; 10(7)2022 Jun 23.
Article em En | MEDLINE | ID: mdl-35891172
ABSTRACT
While suboptimal pneumococcal vaccination rates have been reported in immunosuppressed patients with rheumatic diseases, data for patients with psoriasis (PsO) or atopic dermatitis (AD) are scarce. Pneumococcal vaccination in Germany is recommended in patients with certain comorbidities, immunosuppression, and/or aged 60 years or above. The aim of this multicenter cross-sectional study was to investigate the pneumococcal vaccination rate in patients with PsO compared to patients with AD and to evaluate patient perceptions. All patients completed a questionnaire on vaccination status and perceptions, patient and disease characteristics, as well as comorbidity. Medical records and vaccination certificates were reviewed. Over the whole cohort (n = 327 PsO (41.9% female), n = 98 AD (42.9% female)), 83.8% and 42.9% of PsO and AD patients, respectively, had an indication for pneumococcal vaccination due to immunosuppressive treatment. The pneumococcal vaccination rate was 14.4% and 10.2% in PsO and AD patients, respectively. The vaccination rate depended significantly on age, working status and presence of psoriatic arthritis. The most common reason for nonvaccination was lacking recommendation by physicians. Higher awareness, particularly for vaccination indication due to immunosuppression among dermatologists, general physicians, and patients, is warranted.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Guideline / Observational_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Guideline / Observational_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article